Phase 2RecruitingPriority 3 · Moderate priorityNCT06160843
Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma
Plain-language summary
This Phase 2 trial is testing Pembrolizumab IV infusion Q3W and with daily oral Olaparib. for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 21 Years to 99 Years years
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
- May require specific number of prior treatments
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Pembrolizumab IV infusion Q3W, with daily oral Olaparib. (DRUG): Pembrolizumab IV infusion 200 mg Q3W, with daily oral Olaparib 300mg BID, over a 3-week cycle.
- Drugs / treatments
- Pembrolizumab IV infusion Q3W, with daily oral Olaparib.
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details